

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211919 A1

(51) International Patent Classification:

A61K 31/553 (2006.01) A61K 31/573 (2006.01)
A61K 45/06 (2006.01) A61K 31/7052 (2006.01)
A61P 31/14 (2006.01)

(21) International Application Number:

PCT/US2021/027593

(22) International Filing Date:

16 April 2021 (16.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/011,874 17 April 2020 (17.04.2020) US

(71) Applicant: GENZYME CORPORATION [US/US]; 50
Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: SCHNYDER, Sabine; c/o Genzyme Corpora-
tion, 50 Binney Street, Cambridge, Massachusetts 02142
(US). CAMINIS, John; c/o Genzyme Corporation, 50
Binney Street, Cambridge, Massachusetts 02142 (US).
FLORIAN, Peter; c/o Genzyme Corporation, 50 Binney
Street, Cambridge, Massachusetts 02142 (US). HARRIS,
Keith; c/o Genzyme Corporation, 50 Binney Street, Cam-
bridge, Massachusetts 02142 (US). OFENGHEIM, Dmitry;

c/o Genzyme Corporation, 50 Binney Street, Cambridge,
Massachusetts 02142 (US). STAUDINGER, Heribert; c/
o Genzyme Corporation, 50 Binney Street, Cambridge,
Massachusetts 02142 (US). ZELIC, Matija; c/o Genzyme
Corporation, 50 Binney Street, Cambridge, Massachusetts
02142 (US).

(74) Agent: BAUR, Amelia F. et al.; McNeill Baur PLLC, 125
Cambridge Park Drive, Suite 301, Cambridge, Massachu-
setts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY
RESPONSE




Figure 3

(57) Abstract: This disclosure relates to the field of therapeutic protein kinase inhibitors, in particular receptor-interacting protein kinase 1 ("RIPK1") inhibitor for treatment of subjects with conditions involving systemic hyperinflammatory responses, such as Cytokine Release Syndrome (CRS), or Systemic Inflammatory Response Syndrome (SIRS), sepsis, organ damage, or hyperinflammatory state associated with infectious diseases.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*